ACADIA Pharmaceuticals Targets $1.7B Sales by 2028, Maps Key Remlifansirin Readouts at JPM Conf [Yahoo! Finance]
ACADIA Pharmaceuticals Inc. (ACAD)
Last acadia pharmaceuticals inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.acadia-pharm.com/phoenix.zhtml?c=125180&p=irol-irhome
Company Research
Source: Yahoo! Finance
DAYBUE), calling it an "ambition" not formal guidance and noting growth assumptions include NUPLAZID expansion and European approval for DAYBUE. Remlifansirin is the near-term catalyst: Top-line results from the phase 2 portion of the global Radiant ADP study (318 patients, SAPS-H+D at six weeks) are expected between August and October, and a parallel phase 2 in Lewy body dementia psychosis has been initiated. DAYBUE commercialization and global rollout: DAYBUE—positioned as the first/only Rett syndrome treatment—has treated 2,000 patients with 55% 12-month retention, won approval for the portable "DAYBUE Sticks" formulation with a Q1 limited rollout and full availability by Q2, and is expanding internationally (Israel approval and expected CHMP opinion in Q1 2026). Interested in ACADIA Pharmaceuticals Inc.? Here are five stocks we like better. Acadia Pharmaceuticals: A Mid-Cap Biotech Making Large Moves ACADIA Pharmaceuticals (NASDAQ:ACAD) used its presentation at the 44th
Show less
Read more
Impact Snapshot
Event Time:
ACAD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACAD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACAD alerts
High impacting ACADIA Pharmaceuticals Inc. news events
Weekly update
A roundup of the hottest topics
ACAD
News
- Acadia Pharmaceuticals Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Acadia Pharmaceuticals Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare ConferenceBusiness Wire
- ACADIA Pharmaceuticals (NASDAQ:ACAD) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=ACAD&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StMarketBeat
- ACADIA Pharmaceuticals (NASDAQ:ACAD) was given a new $40.00 price target on by analysts at UBS Group AG. They now have a "buy" rating on the stock.MarketBeat
- ACADIA Pharmaceuticals (NASDAQ:ACAD) had its "buy" rating reaffirmed by analysts at Citigroup Inc..MarketBeat
ACAD
Earnings
- 11/5/25 - Beat
ACAD
Sec Filings
- 1/13/26 - Form 8-K
- 11/19/25 - Form 4
- 11/19/25 - Form 4
- ACAD's page on the SEC website